{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=cohort+2&page=79",
    "query": {
      "intervention": "cohort 2",
      "page": 79
    },
    "page_size": 10
  },
  "pagination": {
    "page": 79,
    "page_size": 10,
    "total_count": 7392,
    "total_pages": 740,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=cohort+2&page=80&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=cohort+2&page=78&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-20T10:33:30.100Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02187861",
      "title": "A Study Evaluating the Safety and Efficacy of Venetoclax (GDC-0199) Plus Bendamustine + Rituximab (BR) in Comparison With BR or Venetoclax Plus Rituximab in Participants With Relapsed and Refractory Follicular Non-Hodgkin's Lymphoma (fNHL)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Follicular Lymphoma"
      ],
      "interventions": [
        {
          "name": "Venetoclax",
          "type": "DRUG"
        },
        {
          "name": "Bendamustine",
          "type": "DRUG"
        },
        {
          "name": "Rituximab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hoffmann-La Roche",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 163,
      "start_date": "2014-12-01",
      "completion_date": "2018-03-16",
      "has_results": true,
      "last_update_posted_date": "2019-06-05",
      "last_synced_at": "2026-11-20T10:33:30.100Z",
      "location_count": 17,
      "location_summary": "Mobile, Alabama • Tucson, Arizona • Los Angeles, California + 12 more",
      "locations": [
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Austell",
          "state": "Georgia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02187861"
    },
    {
      "nct_id": "NCT03082235",
      "title": "Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E6742 in Healthy Adult Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Participants"
      ],
      "interventions": [
        {
          "name": "E6742",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eisai Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "18 Years to 45 Years"
      },
      "enrollment_count": 72,
      "start_date": "2017-03-03",
      "completion_date": "2017-10-11",
      "has_results": false,
      "last_update_posted_date": "2018-09-07",
      "last_synced_at": "2026-11-20T10:33:30.100Z",
      "location_count": 1,
      "location_summary": "Glendale, California",
      "locations": [
        {
          "city": "Glendale",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03082235"
    },
    {
      "nct_id": "NCT02410018",
      "title": "Safety and Effectiveness of OCL 503 in the Treatment of Women With Leiomyomata",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Leiomyomata"
      ],
      "interventions": [
        {
          "name": "OCL 503 (uterine artery embolization)",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "IMBiotechnologies Ltd.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "30 Years",
        "maximum_age": "55 Years",
        "sex": "FEMALE",
        "summary": "30 Years to 55 Years · Female only"
      },
      "enrollment_count": 3,
      "start_date": "2015-04",
      "completion_date": "2016-06",
      "has_results": true,
      "last_update_posted_date": "2018-12-05",
      "last_synced_at": "2026-11-20T10:33:30.100Z",
      "location_count": 1,
      "location_summary": "Albany, New York",
      "locations": [
        {
          "city": "Albany",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02410018"
    },
    {
      "nct_id": "NCT07047820",
      "title": "A Study to Learn More About How Zuranolone Affects Postpartum Depression Symptoms in Participants Who Took it Within 1 Year After The End of Their Pregnancy",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Depression, Postpartum"
      ],
      "interventions": [
        {
          "name": "Zuranolone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Biogen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 305,
      "start_date": "2025-06-30",
      "completion_date": "2026-08-02",
      "has_results": false,
      "last_update_posted_date": "2026-09-08",
      "last_synced_at": "2026-11-20T10:33:30.100Z",
      "location_count": 1,
      "location_summary": "Woonsocket, Rhode Island",
      "locations": [
        {
          "city": "Woonsocket",
          "state": "Rhode Island"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07047820"
    },
    {
      "nct_id": "NCT01744340",
      "title": "A Dose Finding Study of Eribulin Mesylate and Cetuximab For Patients With Advanced Head and Neck and Colon Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Head and Neck Cancer",
        "Colon Cancer"
      ],
      "interventions": [
        {
          "name": "Head and neck",
          "type": "DRUG"
        },
        {
          "name": "Colon- Closed as of May 2014",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "howard safran",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 23,
      "start_date": "2012-05",
      "completion_date": "2015-07",
      "has_results": true,
      "last_update_posted_date": "2020-02-17",
      "last_synced_at": "2026-11-20T10:33:30.100Z",
      "location_count": 4,
      "location_summary": "The Bronx, New York • Pawtucket, Rhode Island • Providence, Rhode Island",
      "locations": [
        {
          "city": "The Bronx",
          "state": "New York"
        },
        {
          "city": "Pawtucket",
          "state": "Rhode Island"
        },
        {
          "city": "Providence",
          "state": "Rhode Island"
        },
        {
          "city": "Providence",
          "state": "Rhode Island"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01744340"
    },
    {
      "nct_id": "NCT07219576",
      "title": "Retifanlimab and Ruxolitinib In Solid Malignancies",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Non Small Cell Lung Carcinoma",
        "Renal Cell Carcinoma"
      ],
      "interventions": [
        {
          "name": "Ruxolitinib",
          "type": "DRUG"
        },
        {
          "name": "Retifanlimab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of California, San Diego",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 40,
      "start_date": "2026-01-08",
      "completion_date": "2029-12",
      "has_results": false,
      "last_update_posted_date": "2026-01-13",
      "last_synced_at": "2026-11-20T10:33:30.100Z",
      "location_count": 1,
      "location_summary": "La Jolla, California",
      "locations": [
        {
          "city": "La Jolla",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07219576"
    },
    {
      "nct_id": "NCT02725489",
      "title": "Pilot Study of Durvalumab and Vigil in Advanced Women's Cancers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Breast Cancer",
        "Ovarian Cancer",
        "Fallopian Tube Cancer",
        "Primary Peritoneal Carcinoma",
        "Uterine Cancer",
        "Cervical Cancer",
        "Endometrial Cancer"
      ],
      "interventions": [
        {
          "name": "Vigil",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Durvalumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Mary Crowley Medical Research Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 13,
      "start_date": "2016-06-03",
      "completion_date": "2020-12-02",
      "has_results": false,
      "last_update_posted_date": "2021-01-27",
      "last_synced_at": "2026-11-20T10:33:30.100Z",
      "location_count": 1,
      "location_summary": "Dallas, Texas",
      "locations": [
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02725489"
    },
    {
      "nct_id": "NCT03345823",
      "title": "A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohn's Disease Who Completed the Studies M14-431 or M14-433",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Crohn's Disease"
      ],
      "interventions": [
        {
          "name": "Upadacitinib",
          "type": "DRUG"
        },
        {
          "name": "Placebo for Upadacitinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AbbVie",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 747,
      "start_date": "2018-03-21",
      "completion_date": "2027-09",
      "has_results": false,
      "last_update_posted_date": "2026-04-09",
      "last_synced_at": "2026-11-20T10:33:30.100Z",
      "location_count": 123,
      "location_summary": "Mobile, Alabama • Chandler, Arizona • Scottsdale, Arizona + 97 more",
      "locations": [
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Sun City",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03345823"
    },
    {
      "nct_id": "NCT00100880",
      "title": "Lenalidomide in Treating Young Patients With Recurrent, Progressive, or Refractory CNS Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Childhood Atypical Teratoid/Rhabdoid Tumor",
        "Childhood Central Nervous System Germ Cell Tumor",
        "Childhood Choroid Plexus Tumor",
        "Childhood Craniopharyngioma",
        "Childhood Ependymoblastoma",
        "Childhood Grade I Meningioma",
        "Childhood Grade II Meningioma",
        "Childhood Grade III Meningioma",
        "Childhood High-grade Cerebellar Astrocytoma",
        "Childhood High-grade Cerebral Astrocytoma",
        "Childhood Infratentorial Ependymoma",
        "Childhood Low-grade Cerebellar Astrocytoma",
        "Childhood Low-grade Cerebral Astrocytoma",
        "Childhood Medulloepithelioma",
        "Childhood Mixed Glioma",
        "Childhood Oligodendroglioma",
        "Childhood Supratentorial Ependymoma",
        "Recurrent Childhood Brain Tumor",
        "Recurrent Childhood Cerebellar Astrocytoma",
        "Recurrent Childhood Cerebral Astrocytoma",
        "Recurrent Childhood Ependymoma",
        "Recurrent Childhood Medulloblastoma",
        "Recurrent Childhood Pineoblastoma",
        "Recurrent Childhood Subependymal Giant Cell Astrocytoma",
        "Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor",
        "Recurrent Childhood Visual Pathway and Hypothalamic Glioma"
      ],
      "interventions": [
        {
          "name": "lenalidomide",
          "type": "DRUG"
        },
        {
          "name": "perfusion-weighted magnetic resonance imaging",
          "type": "PROCEDURE"
        },
        {
          "name": "diffusion-weighted magnetic resonance imaging",
          "type": "PROCEDURE"
        },
        {
          "name": "laboratory biomarker analysis",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE",
        "OTHER"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "21 Years",
        "sex": "ALL",
        "summary": "Up to 21 Years"
      },
      "enrollment_count": 45,
      "start_date": "2004-11",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2013-09-30",
      "last_synced_at": "2026-11-20T10:33:30.100Z",
      "location_count": 1,
      "location_summary": "Memphis, Tennessee",
      "locations": [
        {
          "city": "Memphis",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00100880"
    },
    {
      "nct_id": "NCT04683003",
      "title": "A Study of TAK-755 in Participants With Congenital Thrombotic Thrombocytopenic Purpura",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Thrombotic Thrombocytopenic Purpura (TTP)"
      ],
      "interventions": [
        {
          "name": "TAK-755",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Takeda",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "0 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "0 Years to 70 Years"
      },
      "enrollment_count": 77,
      "start_date": "2021-04-14",
      "completion_date": "2027-03-16",
      "has_results": false,
      "last_update_posted_date": "2026-04-02",
      "last_synced_at": "2026-11-20T10:33:30.100Z",
      "location_count": 5,
      "location_summary": "Atlanta, Georgia • Buffalo, New York • Durham, North Carolina + 2 more",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Buffalo",
          "state": "New York"
        },
        {
          "city": "Durham",
          "state": "North Carolina"
        },
        {
          "city": "Dublin",
          "state": "Ohio"
        },
        {
          "city": "Oklahoma City",
          "state": "Oklahoma"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04683003"
    }
  ]
}